Tal Givoly, co-founder and CEO of Medivisor, outlines the entrepreneurial and academic background of co-founder Dr. Oren Fierst.
Opinion
Givoly: WebMD's information is static and fails to reflect new research
“WebMD's information is essentially fairly static. There's a page about lymphoma and about treatment options, but it doesn't get updated every research paper that gets updated.”
Prediction Not checkable as stated
Givoly: Biopharma will eventually become Medivisor's largest revenue stream
“So, ultimately, over time, it's going to be, ah, basically, ah, the biopharma is gonna be larger.”
Disclosure
Givoly: Medivisor revenue is split fifty-fifty between licensing and biopharma
“Today it's about fifty-fifty.”
Assertion Not checkable as stated
Givoly: Medivisor has over 130,000 subscribers across 129 countries
“We're, by the way, helping over 130,000 subscribers. In a 129 countries, though the vast majority are in the US.”
Disclosure
Givoly: Medivisor's clinical trial acceleration deals are six-figure contracts
“It's usually bigger, longer deals to longer term engagement. So, for example, a clinical trial that wants to be accelerated, it could be a six-figure deal to work with us to help accelerate that trial.”
Assertion Not checkable as stated
Givoly: Medivisor's last four biopharma deals closed inbound within three months
“So far, the interesting thing is that the last four deals have come to us and closed within three months. So without us even meeting them. So yeah, we had phone conversations and so on, but the last deals have actually discovered us online found out that we co…”